Cannprisma Magazine 01/2025

The Cannprisma Story:?

Pioneering Pharmaceutical Excellence

Dear Valued Partners,?

Welcome to Chapter 3 of the Cannprisma Story, where we take you through our journey from cultivation to full-scale pharmaceutical production. In this edition, we'll explore how we've positioned ourselves as a leading Medical Cannabis Hub in the European market.

Chapter 3: From Plant to Pharmaceutical

7. EU-GMP Part I Certification - February 2023

?In February 2023, we achieved a crucial milestone by obtaining the EU-GMP (European Union Good Manufacturing Practice) Part I license. This certification validated our commitment to producing cannabis medicines and preparations that are safe, consistent, and effective.

EU-GMP Part I ensures that medicinal products are consistently produced and controlled to the quality standards appropriate for their intended use.? This certification opened new doors for Cannprisma:?

- Expanded product range

- Broader market reach

- Ability to produce various cannabis-based medications compliant with regulatory requirements

8. EU-GMP Part II Certification - February 2023

?Simultaneously, we secured the EU-GMP Part II license, enabling us to manufacture? active pharmaceutical ingredients (APIs). This achievement was pivotal in establishing? our role as a medical cannabis hub.?

??

With this certification, we can now:

- Produce high-quality cannabis-based APIs

-Assist licenced producers in bringing their flowers to European markets

- Streamline the pathway from cultivation to patient-ready products.

As our Qualified Person Fernando àguas said at the time “Obtaining both EU-GMP Part I and II certifications at the same time is a significant achievement for our team. These certifications?validate our commitment to quality throughout our production process. The Part II certification confirms that our active ingredients meet high quality standards, while Part I ensures our final products are manufactured with care and precision. Together, these certifications strengthen our position in the European medical cannabis market and reinforce our commitment to providing safe, high-quality products for patients."

9. Submission of First MAs for the Portuguese Market - June 2024

?In June 2024, we proudly submitted our first Marketing Authorization (MA) applications to Infarmed, aiming to introduce two dried cannabis flower products to the Portuguese market.

This milestone represents:?

- Our first direct contribution to Portuguese patients?

- Expanded access to high-quality, effective cannabis-based treatments?

- A step towards improving quality of life for many patients? ?

By the Numbers:?

- 2 dried cannabis flower products submitted for approval?

- Potential to help thousands of Portuguese patients?

- Months of rigorous testing and documentation

?Looking Ahead Always Eager for More!? ?

As we continue to grow and innovate, our focus remains on expanding access to medical cannabis and supporting patient health through scientifically backed cannabis therapies.?

In our next and final chapter, we'll explore how Cannprisma is shaping the future of medical cannabis in Europe. Stay tuned to learn about our latest developments and our vision for the years to come.?

Do you have questions about our journey to pharmaceutical excellence? We'd love to hear from you!?

Send us your thoughts via our social media accounts or comment below!

?